Business Description
Guiyang Xintian Pharmaceutical Co Ltd
ISIN : CNE100002QB5
Share Class Description:
SZSE:002873: Class ACompare
Compare
Traded in other countries / regions
002873.China IPO Date
2017-05-19Description
Guiyang Xintian Pharmaceutical Co Ltd is a Chinese medical research and production company. The company manufactures medicines including capsule, tablet, wine agent, mixture, LOU agent, syrup agent, suspension agent, powder, granule and gel agent.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.2 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.7 | |||||
| Debt-to-EBITDA | 7.39 | |||||
| Interest Coverage | 8.14 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.36 | |||||
| Beneish M-Score | -2.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.6 | |||||
| 3-Year EBITDA Growth Rate | 17.6 | |||||
| 3-Year EPS without NRI Growth Rate | -19 | |||||
| 3-Year Book Growth Rate | 10.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.25 | |||||
| 9-Day RSI | 40.17 | |||||
| 14-Day RSI | 38.49 | |||||
| 6-1 Month Momentum % | -23.45 | |||||
| 12-1 Month Momentum % | -29.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.97 | |||||
| Quick Ratio | 0.67 | |||||
| Cash Ratio | 0.22 | |||||
| Days Inventory | 321.82 | |||||
| Days Sales Outstanding | 99.62 | |||||
| Days Payable | 152.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.85 | |||||
| Dividend Payout Ratio | 0.35 | |||||
| 3-Year Dividend Growth Rate | 25.2 | |||||
| Forward Dividend Yield % | 0.85 | |||||
| 5-Year Yield-on-Cost % | 2.1 | |||||
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | -8.25 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.99 | |||||
| Operating Margin % | 10.53 | |||||
| Net Margin % | 7.73 | |||||
| FCF Margin % | 1.93 | |||||
| ROE % | 6.33 | |||||
| ROA % | 3.65 | |||||
| ROIC % | 4.76 | |||||
| ROC (Joel Greenblatt) % | 9.95 | |||||
| ROCE % | 7.04 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 28.47 | |||||
| PE Ratio without NRI | 28.87 | |||||
| Shiller PE Ratio | 26.35 | |||||
| PEG Ratio | 2.02 | |||||
| PS Ratio | 2.18 | |||||
| PB Ratio | 1.86 | |||||
| Price-to-Tangible-Book | 2.24 | |||||
| Price-to-Free-Cash-Flow | 115.08 | |||||
| Price-to-Operating-Cash-Flow | 20.33 | |||||
| EV-to-EBIT | 25.49 | |||||
| EV-to-EBITDA | 25.49 | |||||
| EV-to-Revenue | 2.67 | |||||
| EV-to-FCF | 141.52 | |||||
| Price-to-Projected-FCF | 2.84 | |||||
| Price-to-DCF (Earnings Based) | 1.66 | |||||
| Price-to-DCF (FCF Based) | 9.96 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.75 | |||||
| Price-to-Graham-Number | 1.7 | |||||
| Earnings Yield (Greenblatt) % | 3.92 | |||||
| FCF Yield % | 0.95 | |||||
| Forward Rate of Return (Yacktman) % | 5.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guiyang Xintian Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 922.549 | ||
| EPS (TTM) (Â¥) | 0.287 | ||
| Beta | 1.07 | ||
| Volatility % | 48.6 | ||
| 14-Day RSI | 38.49 | ||
| 14-Day ATR (Â¥) | 0.311101 | ||
| 20-Day SMA (Â¥) | 8.402 | ||
| 12-1 Month Momentum % | -29.16 | ||
| 52-Week Range (Â¥) | 7.59 - 14.33 | ||
| Shares Outstanding (Mil) | 229.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guiyang Xintian Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guiyang Xintian Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guiyang Xintian Pharmaceutical Co Ltd Frequently Asked Questions
What is Guiyang Xintian Pharmaceutical Co Ltd(SZSE:002873)'s stock price today?
The current price of SZSE:002873 is ¥8.17. The 52 week high of SZSE:002873 is ¥14.33 and 52 week low is ¥7.59.
When is next earnings date of Guiyang Xintian Pharmaceutical Co Ltd(SZSE:002873)?
The next earnings date of Guiyang Xintian Pharmaceutical Co Ltd(SZSE:002873) is .
Does Guiyang Xintian Pharmaceutical Co Ltd(SZSE:002873) pay dividends? If so, how much?
The Dividend Yield %  of Guiyang Xintian Pharmaceutical Co Ltd(SZSE:002873) is 0.85% (As of Today), Highest Dividend Payout Ratio of Guiyang Xintian Pharmaceutical Co Ltd(SZSE:002873) was 0.35. The lowest was 0.09. And the median was 0.16. The  Forward Dividend Yield % of Guiyang Xintian Pharmaceutical Co Ltd(SZSE:002873) is 0.85%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers